Wellington Management Group
VIRX

Wellington Management Group’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Wellington Management Group’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-994
Closed -$1.03M – 2241
2013
Q3 		$1.03M Hold
994
– – ﹤0.01% 1789
2013
Q2 		$1.09M Buy
+994
New +$1.11M ﹤0.01% 1749

Other funds holding VIRX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

Wellington Management Group's VIRX Position: Q4 2013 in Review

Wellington Management Group sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2013, closing a stake of 994 shares — an estimated $1.03M sold.

Wellington Management Group first reported a position in VIRX in Q2 2013 and held it in 2 quarters. The position peaked at $1.09M in Q2 2013. 73 funds tracked by Wall St. Rank hold VIRX as of Q4 2013.

  • Wellington Management Group reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2013 after selling out during the quarter.
  • Wellington Management Group sold 994 Viracta Therapeutics, Inc. Common Stock shares in Q4 2013, an estimated $1.03M.
  • Wellington Management Group first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 2 quarters.
  • Wellington Management Group's Viracta Therapeutics, Inc. Common Stock position peaked at $1.09M in Q2 2013.
  • 73 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2013.

Based on Wellington Management Group's 13F filing for Q4 2013, filed 14 Feb 2014.